All Stories

  1. Urothelial carcinoma in situ of the entire urinary tract with invasion into seminal vesicle: A case report
  2. G‐ DISCO : Gemcitabine‐Docetaxel Intravesical Synchronous CO ‐administration – a phase 1 study protocol
  3. Development and psychometric evaluation of a patient-reported symptom index for patients with non-muscle invasive bladder cancer: the NMIBC-SI
  4. Exercise and Psychosexual Education to Improve Sexual Function in Men With Prostate Cancer
  5. Massive tubular ectasia of the rete testes in a patient with Marfan syndrome
  6. A multicentre implementation trial of an Artificial Intelligence-driven biomarker to inform Shared decisions for androgen deprivation therapy in men undergoing prostate radiotherapy: the ASTuTE protocol
  7. Nuclear Medicine and Molecular Imaging in Urothelial Cancer: Current Status and Future Directions
  8. Hypervirulent Klebsiella pneumoniae causing emphysematous pyelonephritis: a life‐threatening pathogen within Australian communities
  9. Cystectomy for bilateral thigh fistulation after salvage radiotherapy for prostate cancer: A case report
  10. Development of a new radical cystectomy surveillance protocol and nurse‐led cystectomy follow‐up clinic in Australia
  11. Predicting Response to Intravesical BCG in High-Risk NMIBC Using an Artificial Intelligence–Powered Pathology Assay: Development and Validation in an International 12-Center Cohort
  12. Immediate Versus Delayed Exercise on Health-related Quality of Life in Patients Initiating Androgen Deprivation Therapy: Results from a Year-long Randomised Trial
  13. An evaluation of durvalumab across the spectrum of urothelial carcinoma
  14. Postoperative anaemia increases unplanned readmission: an international prospective cohort study of patients undergoing major abdominal surgery
  15. Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)
  16. Hypervirulent Klebsiella pneumoniae causing emphysematous pyelonephritis: a life‐threatening pathogen within Australian communities
  17. Durvalumab Injection for Bladder Cancer: First-In-Human Trial
  18. Nurse‐led renal cell carcinoma clinic: a single center review
  19. FDG-PET vs CT in Staging Urothelial Cancer: Improving Metastasis Detection and Treatment Outcomes
  20. Prehabilitative versus rehabilitative exercise in prostate cancer patients undergoing prostatectomy
  21. Solitary fibrous tumour of the urinary bladder – A rare and potentially malignant neoplasm
  22. Relationship between lower urinary tract symptoms (LUTS) and prostate cancer: A persistent myth
  23. Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries
  24. The utility of clinical registries for guiding clinical practice in upper tract urothelial cancer: a narrative review
  25. Lymph node assessment technique matters in radical cystectomy for bladder cancer
  26. Efficacy and Feasibility of Presurgical Exercise in Bladder Cancer Patients Scheduled for Open Radical Cystectomy
  27. Fremantle protocol: Multicenter clinical outcomes for a pragmatic protocol for intravesical bacillus Calmette–Guerin
  28. Analysis of the financial impact and efficiency of the One Stop Prostate Clinic: A same day prostate cancer diagnostic clinic in the Australian public health system
  29. Current trends in penile cancer survivorship amongst remote patients and Aboriginal people in Western Australia
  30. The Evolving Role of Locally Delivered Checkpoint Inhibitors in Non–muscle-invasive Bladder Cancer
  31. Centralization and prospective audit of cystectomy are necessary: a commentary on the case for centralization, supported by a contemporary series utilizing the ANZUP cystectomy database
  32. Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study
  33. 1739P Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: Analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)
  34. Nationwide Industry-Led Community Exercise Program for Men With Locally Advanced, Relapsed, or Metastatic Prostate Cancer on Androgen-Deprivation Therapy
  35. Nomogram predicting the probability of spontaneous stone passage in patients presenting with acute ureteric colic
  36. Intravesical hyaluronic acid with chondroitin sulphate to prevent urinary tract infection after spinal cord injury
  37. Anterior pelvic exenteration and synchronous bilateral nephroureterectomy for BK polyoma virus induced urothelial carcinoma of the bladder: A case report
  38. Weight loss for overweight and obese patients with prostate cancer: a study protocol of a randomised trial comparing clinic-based versus Telehealth delivered EXercise and nutrition intervention (the TelEX trial)
  39. Urethral fistula and perineal collection during intravesical treatment for non-muscle invasive bladder cancer – A rare complication
  40. Technetium‐99 m‐sestamibi single‐photon emission computerised tomography (CT)/CT in the prediction of malignant versus benign small renal masses
  41. 89Zirconium-labelled girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma
  42. SUB-urothelial durvalumab injection: 1 (SUBDUE-1)—Results from the first nine urothelial cancer patients using a dose-escalation schedule.
  43. Unique case of IgG4-related disease of the renal pelvis involving the inferior vena cava masquerading as locally advanced urothelial cancer
  44. A novel technique to remove a urinary bladder foreign body endoscopically using an Endoloop
  45. Interventions for Improving Body Composition in Men with Prostate Cancer: A Systematic Review and Network Meta-analysis
  46. Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study
  47. TREXIT Is Now: Should We Abandon the Transrectal Route for Biopsy? A Three-continent Debate—No
  48. SARS‐CoV‐2 infection and venous thromboembolism after surgery: an international prospective cohort study
  49. Effects of pre‐operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study
  50. ‘Pain‐free TRUS B’: a phase 3 double‐blind placebo‐controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography‐guided prostate biopsy (ANZUP 1501)
  51. Nurse‐led telephone notification of a prostate cancer diagnosis: Prospective analysis of men's preferences for and experiences of a same‐day assessment and diagnostic clinic
  52. Abstract LB036: Clinical value of 18F-FDG-PET compared with CT scan in the detection of nodal and distant metastasis in urothelial carcinoma or bladder cancer
  53. Adenocarcinoma of the urethra: A rare subtype of urethral cancer
  54. A phase I open label dose‐escalation study to evaluate the tolerability, safety and immunological efficacy of sub‐urothelial durvalumab injection in adults with muscle‐invasive or high‐risk non‐muscle‐invasive bladder cancer (SUBDUE‐1, SUB‐urothelial D...
  55. Timing of surgery following SARS-CoV-2 infection
  56. Transrectal ultrasound biopsy of the prostate: does it still have a role in prostate cancer diagnosis?
  57. Ten‐year outcomes of the first ‘one‐stop haematuria clinic’ in an Australian public hospital
  58. Multi-route antifungal administration in the management of urinary Candida glabrata bezoar
  59. Open partial nephrectomy for a collision renal cell carcinoma in a transplant kidney: A case report
  60. ‘One Stop Prostate Clinic’: prospective analysis of 1000 men attending a public same‐day prostate cancer assessment and/or diagnostic clinic
  61. Gender discrepancies in bladder cancer: potential explanations
  62. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250]
  63. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
  64. Timing of exercise for muscle strength and physical function in men initiating ADT for prostate cancer
  65. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†
  66. Painless Visible Haematuria in Adults: An Algorithmic Approach Guiding Management
  67. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
  68. National Speakers
  69. Factors associated with spontaneous stone passage in a contemporary cohort of patients presenting with acute ureteric colic: results from the Multi‐centre cohort study evaluating the role of Inflammatory Markers In patients presenting with acute u...
  70. An inventive two-catheter technique to manage an extra-peritoneally ruptured and prolapsed bladder causing obstructive uropathy
  71. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition
  72. Co-existing renal myelolipoma and renal cell carcinoma: A case report
  73. Can exercise delay transition to active therapy in men with low-grade prostate cancer? A multicentre randomised controlled trial
  74. Intratesticular pseudoaneurysm secondary to orchitis: A case report
  75. Transrectal prostate biopsy sepsis rate following reduced quinolone antibiotic prophylaxis from six doses to single dose
  76. Metastatic primary testicular carcinoid tumor managed with radical orchiectomy, retroperitoneal lymph node dissection and inferior vena cava excision: Case report
  77. Delays in the diagnosis and initial treatment of bladder cancer in Western Australia
  78. BCG + Mitomycin trial for high‐risk non‐muscle‐invasive bladder cancer: progress report and lessons learned
  79. Bladder cancer – Old lessons yet to be learned
  80. Neobladder Obstruction: A Non-ischemic Cause for Hepatic Portal Venous Gas: Case Report
  81. ProCare Trial: a phase II randomized controlled trial of shared care for follow‐up of men with prostate cancer
  82. Enhancing active surveillance of prostate cancer: the potential of exercise medicine
  83. Pure small cell carcinoma of the prostate preceded by acute zonal occult outer retinopathy: A case report
  84. A ‘One Stop’ Prostate Clinic for rural and remote men: a report on the first 200 patients
  85. BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301)
  86. Retrograde ureteric stent insertion in the management of infected obstructed kidneys
  87. The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group – a new co‐operative cancer trials group in genitourinary oncology
  88. Radical cystectomy in Australia
  89. A randomised controlled trial comparing use of lignocaine periprostatic nerve block alone and combined with diclofenac suppository for patients undergoing transrectal ultrasound ( TRUS )‐guided prostat...
  90. The conservative management of renal trauma: a literature review and practical clinical guideline from A ustralia and N ew Z<...
  91. Using mobile technology to overcome language barriers in medicine
  92. Current trends in bladder cancer in Australia
  93. The outcome of a multi-centre feasibility study of online adaptive radiotherapy for muscle-invasive bladder cancer TROG 10.01 BOLART
  94. Protocol for the ProCare Trial: a phase II randomised controlled trial of shared care for follow-up of men with prostate cancer
  95. First Report of the Stapled Mesh Stoma Reinforcement Technique in a Urologic Context
  96. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis
  97. Intravesical therapies for bladder cancer – indications and limitations
  98. ‘One stop’ haematuria clinic in Fremantle Hospital, Western Australia: a report of the first 500 patients
  99. Re: Willem Oosterlinck, Ziya Kirkali, Richard Sylvester, et al. Sequential Intravesical Chemoimmunotherapy with Mitomycin C and Bacillus Calmette-Guérin and with Bacillus Calmette-Guérin Alone in Patients with Carcinoma in Situ of the Urinary Bladder: ...
  100. EORTC radiation proctitis-specific quality of life module – Pretesting in four European countries
  101. Ultrasensitive Prostate Specific Antigen Assay Following Laparoscopic Radical Prostatectomy – An Outcome Measure for Defining the Learning Curve
  102. Hyperbaric Oxygen Treatment of Chronic Refractory Radiation Proctitis: A Randomized and Controlled Double-Blind Crossover Trial With Long-Term Follow-Up: In Regard to Clarke et al. (Int J Radiat Oncol Biol Phys 2008 Mar 12)
  103. Nanotechnology and Its Relevance to the Urologist
  104. Delayed presentation of arteriovenous fistula 20 years after blunt renal trauma
  105. Survey of Endourology
  106. NURSE‐LED FLEXIBLE CYSTOSCOPY: EXPERIENCE FROM ONE UK CENTRE
  107. A Prospective, Randomized Trial Comparing Conventional Transurethral Prostate Resection With PlasmaKinetic® Vaporization of the Prostate: Physiological Changes, Early Complications and Long-Term Followup
  108. Randomized, placebo‐controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks
  109. 1449: Finasteride Rapidly Reduces Prostatic Vascularity: A Randomized Placebo Controlled Study
  110. New phosphodiesterase inhibitors in the treatment of erectile dysfunction
  111. Allogeneic stem-cell transplantation for renalcellcancer
  112. CURRENT TRENDS IN BLADDER CANCER IN ENGLAND AND WALES
  113. Pharmacological management of metastatic boney pain
  114. Physiologic Changes of the Anorectum After Pelvic Radiotherapy for the Treatment of Prostate and Bladder Cancer
  115. Luteinising hormone releasing hormone analogues in the treatment of prostate cancer
  116. Current Trends in Colorectal Cancer: Site, Incidence, Mortality and Survival in England and Wales
  117. First Report of an Isolated Jejunal Seminoma: Presentation with Melaena and Iron Deficiency Anaemia
  118. HEMANGIOPERICYTOMA OF THE SEMINAL VESICLE PRESENTING WITH HYPOGLYCEMIA
  119. HEMANGIOPERICYTOMA OF THE SEMINAL VESICLE PRESENTING WITH HYPOGLYCEMIA
  120. Primary anterior urethral transitional cell carcinoma: a rare tumour
  121. Anorectal injury following pelvic radiotherapy
  122. Anorectal Irradiation in Pelvic Radiotherapy: An Assessment Using in-vivo Dosimetry
  123. Massive Mediastinal Seminoma Post-orchidectomy Late relapse with Skip-metastases or New Primary?